Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dr Reddy's Laboratories has started dosing in a randomized, double blind, placebo controlled, parallel group Phase II trial of DRL-17822 in patients suffering from type II dyslipidemia.
Subscribe to our email newsletter
The study aims to investigate the safety and efficacy of DRL-17822 in patients with type-II dyslipidemia.
In the study, three doses (50, 150 & 300mg) of DRL-17822 given once daily for 4 weeks will be investigated.
Dr Reddy’s founder chairman Anji Reddy said this class of therapy can transform the treatment of CHD and DRL-17822 is in a position to be one of the front-running products in the class.